GLSI trades 152.5% below Wall Street's consensus target of $50.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes GLSI achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 29, 2026, Greenwich LifeSciences, Inc. (GLSI) has a Wall Street consensus price target of $50.00, based on estimates from 2 covering analysts. With the stock currently trading at $19.80, this represents a potential upside of +152.5%. The company has a market capitalization of $291M.
Analyst price targets range from a low of $50.00 to a high of $50.00, representing a 0% spread in expectations. The median target of $50.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, GLSI trades at a trailing P/E of -13.8x. Analysts expect EPS to grow +9.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NKTRNektar Therapeutics | $1.2B | $63.65 | $149.60 | +135.0% | Buy | — | 33 |
HALOHalozyme Therapeutics, Inc. | $8.9B | $74.96 | $88.25 | +17.7% | Buy | 9.2x | 27 |
INVAInnoviva, Inc. | $1.7B | $23.57 | $37.00 | +57.0% | Buy | 6.6x | 10 |
EXELExelixis, Inc. | $13.9B | $54.77 | $47.83 | -12.7% | Buy | 15.6x | 33 |
RCUSArcus Biosciences, Inc. | $3.1B | $31.00 | $31.00 | +0.0% | Buy | — | 18 |
AGENAgenus Inc. | $131M | $3.15 | $7.33 | +141.9% | Buy | 3.9x | 11 |
CLDXCelldex Therapeutics, Inc. | $2.3B | $35.26 | $49.00 | +39.0% | Buy | — | 19 |
NUVBNuvation Bio Inc. | $2.0B | $5.65 | $13.00 | +130.1% | Buy | — | 9 |
IMVTImmunovant, Inc. | $8.0B | $38.85 | $45.00 | +15.8% | Buy | — | 23 |
LLYEli Lilly and Company | $1.1T | $1206.51 | $1269.94 | +5.3% | Buy | 33.0x | 45 |
Quick answers to the most common questions about buying GLSI stock.
The consensus Wall Street price target for GLSI is $50, representing 152.5% upside from the current price of $19.8. With 2 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
GLSI has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $50 implies 152.5% upside from current levels.
GLSI's current price is $19.8 with a consensus target of $50 (152.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $50 for GLSI, while the most conservative target is $50. The consensus of $50 represents the median expectation. These targets typically reflect 12-month expectations.
GLSI is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month GLSI stock forecast based on 2 Wall Street analysts shows a consensus price target of $50, with estimates ranging from $50 (bear case) to $50 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on GLSI, with a "Buy" consensus rating and $50 price target (152.5% upside). 2 of 2 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
GLSI analyst price targets range from $50 to $50, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $50 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.